iPSC-Derived Cells Enable Drug Discovery & Cell Therapy Research

Benefits

• Improved model fidelity over cell lines and biochemical assays
• Improved throughput and cost over animal models
• Applications include disease modelling, personalized medicine, drug screening and toxicity testing

PBMC-derived human iPS cells were engineered to express Cas9 (Streptococcus pyogenes CRISPR associated protein 9) either constitutively or upon doxycyclin induction (tet-on). These cells can be transfected or transduced with a cDNA encoding single-guide RNA(s) targeting specific gene(s) of interest to generate knockout, mutated, or knockin cells. The inducible cells allow temporal control of Cas9 expression, which limits the occurrence of off-target modifications.

• Cas9 Expressing iPS Cell Pool

• Cas9 Inducible (Tet-On) iPS Cell Pool

StemBright™ Reporter iPSCs are engineered to express a conditional reporter gene that will respond to the activation of a transcription factor within a cell signaling pathway of interest, or to constitutively express luciferase or eGFP for cell tracking. For example, Wnt signaling is involved in the cell cycle re-entry of iPSC-derived cardiomyocytes. The TCF/LEF (Wnt) Luciferase Reporter iPS Cell pool responds to Wnt pathway activators with a quantitative, dose-dependent increase in luciferase activity. These pluripotent reporter cells can also be used to generate differentiated reporter cells.

• StemBright^™ Luciferase iPS Cell Pool

• TCF/LEF StemBright^™ Luciferase iPS Cell Pool (Wnt Pathway)

Eliminating the expression of a cellular protein can provide valuable research insights. Using CRISPR/Cas9 technology, we can effectively knockout target proteins to change cellular properties as desired. For example, our B2M Knockout iPS Cell Line has the full functional capacity of iPSCs, but has very low immunogenicity, providing a useful tool for allogeneic cell therapy research.